secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211843
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports positive Phase 3 X-TOLE2 data for azetukalner; NDA submission planned Q3 2026
--------------------------------------------------------------------------------

- Phase 3 X-TOLE2 met primary endpoint: median percent change in monthly FOS -53.2% (25mg) and -34.5% (15mg) vs -10.4% placebo (p<0.0001).
- NDA submission to FDA planned Q3 2026 based on X-TOLE2 and X-TOLE data.
- Cash and marketable securities $1.34B as of March 31; cash runway into 2029. Net loss $102.3M for Q1 2026.
- Enrollment ongoing for additional Phase 3 studies: X-TOLE3 (FOS), X-ACKT (PGTCS), X-NOVA2/3 (MDD), X-CEED (BPD); X-NOVA2 topline H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526211843/0001193125-26-211843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526211843/xene-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer